Literature DB >> 11112459

Fucoidan inhibits smooth muscle cell proliferation and reduces mitogen-activated protein kinase activity.

P Religa1, M Kazi, J Thyberg, Z Gaciong, J Swedenborg, U Hedin.   

Abstract

OBJECTIVES AND
DESIGN: fucoidan has previously been shown to inhibit the proliferation of arterial smooth muscle cells both in animal models and in vitro. However, the mechanisms behind the anti-proliferative effects of this polysulfated polysaccharide are not known in detail. Here, the inhibitory effect of fucoidan on rat aortic smooth muscle cell proliferation was examined and compared with the effects of heparin after stimulation with fetal calf serum, platelet-derived growth factor BB, basic fibroblast growth factor, heparin-binding epidermal growth factor, and angiotensin II.
MATERIALS AND METHODS: the cultures were analysed with respect to cell proliferation and DNA synthesis by cell counting and measurement of(3)H-thymidine incorporation. Phosphorylation of mitogen-activated protein kinase and nuclear translocation of phosphorylated mitogen-activated protein kinase were studied by immunoblotting and immunocytochemistry.
RESULTS: fucoidan was shown to be a more potent inhibitor of smooth muscle cell proliferation than heparin. Fucoidan also reduced growth factor-induced activation of mitogen-activated protein kinase and prevented nuclear translocation of phosphorylated mitogen-activated protein kinase.
CONCLUSION: fucoidan is a more potent anti-proliferative polysulphated polysaccharide than heparin and may mediate its effects through inhibition of the mitogen-activated protein kinase pathway in a similar manner as heparin. Copyright 2000 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11112459     DOI: 10.1053/ejvs.2000.1220

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  7 in total

1.  Fucoidan promotes early step of cardiac differentiation from human embryonic stem cells and long-term maintenance of beating areas.

Authors:  Sofiane Hamidi; Didier Letourneur; Rachida Aid-Launais; Antonio Di Stefano; William Vainchenker; Françoise Norol; Catherine Le Visage
Journal:  Tissue Eng Part A       Date:  2014-02-14       Impact factor: 3.845

2.  Fucoidan functionalization on poly(vinyl alcohol) hydrogels for improved endothelialization and hemocompatibility.

Authors:  Yuan Yao; Aung Moe Zaw; Deirdre E J Anderson; Monica T Hinds; Evelyn K F Yim
Journal:  Biomaterials       Date:  2020-04-01       Impact factor: 12.479

3.  Biological effects of fucoidan isolated from Fucus vesiculosus on thrombosis and vascular cells.

Authors:  Kyu-Won Kwak; Kil-Sang Cho; Ok-Jin Hahn; Kwang-Hyung Lee; Boo-Yong Lee; Jung-Jae Ko; Kwang-Hoe Chung
Journal:  Korean J Hematol       Date:  2010-03-31

4.  Overexpression of CD39/nucleoside triphosphate diphosphohydrolase-1 decreases smooth muscle cell proliferation and prevents neointima formation after angioplasty.

Authors:  K Koziak; M Bojakowska; S C Robson; K Bojakowski; J Soin; E Csizmadia; P Religa; Z Gaciong; E Kaczmarek
Journal:  J Thromb Haemost       Date:  2008-07-01       Impact factor: 5.824

5.  Anticancer drugs from marine flora: an overview.

Authors:  N Sithranga Boopathy; K Kathiresan
Journal:  J Oncol       Date:  2011-02-27       Impact factor: 4.375

Review 6.  Marine polysaccharides: therapeutic efficacy and biomedical applications.

Authors:  Young-Eun Lee; Hyeongmin Kim; Changwon Seo; Taejun Park; Kyung Bin Lee; Seung-Yup Yoo; Seong-Chul Hong; Jeong Tae Kim; Jaehwi Lee
Journal:  Arch Pharm Res       Date:  2017-09-16       Impact factor: 4.946

Review 7.  Current Research Landscape of Marine-Derived Anti-Atherosclerotic Substances.

Authors:  Qi Cao; Jiarui Zhao; Maochen Xing; Han Xiao; Qian Zhang; Hao Liang; Aiguo Ji; Shuliang Song
Journal:  Mar Drugs       Date:  2020-08-25       Impact factor: 5.118

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.